Controlling MTORC1 Activity as a Novel Therapeutic Strategy for Managing Human Hair Growth and Pigmentation
New to Rapamycin? There is a guide in the encyclopedia. Read the guide →
Studysummary This study found that inhibiting mTORC1 activity with rapamycin significantly increased melanin production and extended hair growth phase in human hair follicles, suggesting potential for managing hair growth and pigmentation disorders.
Our plain-language summary. Not medical advice or a treatment recommendation. Consult a qualified healthcare professional before changing treatment. Full disclaimer
The study investigates the role of mechanistic Target of Rapamycin Complex 1 (mTORC1) in human hair follicle (HF) biology, particularly focusing on hair growth and pigmentation. Using HF organ culture, researchers found that inhibiting mTORC1 with rapamycin significantly increased melanin production, gp100 expression, tyrosinase activity, and melanocyte dendricity in healthy human anagen scalp HFs. This effect was linked to increased a-MSH production by keratinocytes, especially in graying HFs, where rapamycin could even re-stimulate melanogenesis. Conversely, excessive mTORC1 activity reduced HF pigmentation. Additionally, rapamycin prolonged the anagen phase and inhibited hair matrix keratinocyte apoptosis, suggesting its potential for managing hair growth and pigmentation disorders. The findings highlight mTORC1's fundamental role in HF cycling and pigmentation, proposing rapamycin and rapalogs as novel therapeutic strategies.
